Brenna LaBere1, Maria J Gutierrez2, Hannah Wright3, Elizabeth Garabedian4, Hans D Ochs5, Ramsay L Fuleihan6, Elizabeth Secord7, Rebecca Marsh8, Kathleen E Sullivan9, Charlotte Cunningham-Rundles10, Luigi D Notarangelo11, Karin Chen12. 1. Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah; Division of Immunology, Boston Children's Hospital, Boston, Mass. 2. Division of Pediatric Allergy and Immunology, Johns Hopkins University, Baltimore, Md. 3. United States Immunodeficiency Network, Towson, Md. 4. National Institutes of Health, National Human Genome Research Institute, Bethesda, Md. 5. Division of Immunology, Department of Pediatrics, University of Washington and Seattle Children's Research Institute, Seattle, Wash. 6. Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, Columbia University Irving Medical Center, New York-Presbyterian and Morgan Stanley Children's Hospital, New York, NY. 7. Division of Allergy and Immunology, Wayne Pediatrics, Wayne State University School of Medicine, Detroit, Mich. 8. Department of Pediatrics, University of Cincinnati, and Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 9. Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pa. 10. Division of Allergy and Immunology, Department of Medicine, the Icahn School of Medicine at Mount Sinai, New York, NY. 11. Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. 12. Division of Allergy and Immunology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah; Division of Immunology, Department of Pediatrics, University of Washington and Seattle Children's Research Institute, Seattle, Wash. Electronic address: Karin.Chen@SeattleChildrens.org.
Abstract
BACKGROUND: Chronic granulomatous disease (CGD) is an inborn error of immunity caused by defects in the phagocytic nicotinamide adenine dinucleotide phosphate oxidase complex, leading to increased susceptibility to infection and inflammatory autoimmune diseases. Up to 50% of patients have gastrointestinal (GI) involvement and meet diagnostic criteria for inflammatory bowel disease (CGD-IBD). OBJECTIVE: We analyzed patients with CGD from the US Immunodeficiency Network (USIDNET) registry to determine whether IBD changes the presentation, treatment, and outcomes of patients with CGD. METHODS: A retrospective evaluation of CGD cases from the USIDNET registry was completed. CGD-IBD was defined as the presence of any major physician-reported inflammatory, noninfectious GI disease manifestation. Demographic information, conditions, infections, antimicrobial therapies, immunomodulator use, and hematopoietic stem cell transplantation data were analyzed. RESULTS: Of 194 patients with a diagnosis of CGD, 96 met criteria for IBD and 98 were categorized in the non-IBD group. Patients with CGD-IBD had an increased rate of infection compared with the non-IBD group (0.66 vs 0.36 infections/patient/year). Enteric organism infections were more common in patients with IBD. Immunomodulators were used at a significantly higher percentage in patients with IBD compared with patients without IBD (80% vs 56%, P < .001). Of the entire CGD cohort, 17 patients died (8.8%), with no significant difference between patients with IBD and patients without IBD (P = 1.00). CONCLUSION: Infectious events, enteric organism infections, and use of immunomodulatory drugs were higher in patients with IBD than patients without IBD; however, mortality was not increased. Patients with CGD and concurrent IBD are at increased risk for disease complications, supporting the importance of early recognition, diagnosis, and treatment.
BACKGROUND: Chronic granulomatous disease (CGD) is an inborn error of immunity caused by defects in the phagocytic nicotinamide adenine dinucleotide phosphate oxidase complex, leading to increased susceptibility to infection and inflammatory autoimmune diseases. Up to 50% of patients have gastrointestinal (GI) involvement and meet diagnostic criteria for inflammatory bowel disease (CGD-IBD). OBJECTIVE: We analyzed patients with CGD from the US Immunodeficiency Network (USIDNET) registry to determine whether IBD changes the presentation, treatment, and outcomes of patients with CGD. METHODS: A retrospective evaluation of CGD cases from the USIDNET registry was completed. CGD-IBD was defined as the presence of any major physician-reported inflammatory, noninfectious GI disease manifestation. Demographic information, conditions, infections, antimicrobial therapies, immunomodulator use, and hematopoietic stem cell transplantation data were analyzed. RESULTS: Of 194 patients with a diagnosis of CGD, 96 met criteria for IBD and 98 were categorized in the non-IBD group. Patients with CGD-IBD had an increased rate of infection compared with the non-IBD group (0.66 vs 0.36 infections/patient/year). Enteric organism infections were more common in patients with IBD. Immunomodulators were used at a significantly higher percentage in patients with IBD compared with patients without IBD (80% vs 56%, P < .001). Of the entire CGD cohort, 17 patients died (8.8%), with no significant difference between patients with IBD and patients without IBD (P = 1.00). CONCLUSION: Infectious events, enteric organism infections, and use of immunomodulatory drugs were higher in patients with IBD than patients without IBD; however, mortality was not increased. Patients with CGD and concurrent IBD are at increased risk for disease complications, supporting the importance of early recognition, diagnosis, and treatment.
Authors: Christine Deffert; Maria L Olleros; Yuan Huiping; François R Herrmann; Dina Zekry; Irene Garcia; Karl-Heinz Krause; Michela G Schäppi Journal: J Allergy Clin Immunol Date: 2011-05-18 Impact factor: 10.793
Authors: Gulbu Uzel; Jordan S Orange; Nina Poliak; Beatriz E Marciano; Theo Heller; Steven M Holland Journal: Clin Infect Dis Date: 2010-11-08 Impact factor: 9.079
Authors: Robert Chiesa; Junfeng Wang; Henric-Jan Blok; Sheree Hazelaar; Benedicte Neven; Despina Moshous; Ansgar Schulz; Manfred Hoenig; Fabian Hauck; Amal Al Seraihy; Jolanta Gozdzik; Per Ljungman; Caroline A Lindemans; Juliana F Fernandes; Krzysztof Kalwak; Brigitte Strahm; Urs Schanz; Petr Sedlacek; Karl-Walter Sykora; Serap Aksoylar; Franco Locatelli; Polina Stepensky; Robert Wynn; Su Han Lum; Marco Zecca; Fulvio Porta; Mervi Taskinen; Brenda Gibson; Susanne Matthes; Musa Karakukcu; Mathias Hauri-Hohl; Paul Veys; Andrew R Gennery; Giovanna Lucchini; Matthias Felber; Michael H Albert; Dmitry Balashov; Arjan Lankester; Tayfun Güngör; Mary A Slatter Journal: Blood Date: 2020-09-03 Impact factor: 22.113
Authors: Beatriz E Marciano; Robert Wesley; Ellen S De Carlo; Victoria L Anderson; Lisa A Barnhart; Dirk Darnell; Harry L Malech; John I Gallin; Steven M Holland Journal: Clin Infect Dis Date: 2004-08-16 Impact factor: 9.079
Authors: Daniel J B Marks; Kana Miyagi; Farooq Z Rahman; Marco Novelli; Stuart L Bloom; Anthony W Segal Journal: Am J Gastroenterol Date: 2009-01 Impact factor: 10.864
Authors: L B K R Jones; P McGrogan; T J Flood; A R Gennery; L Morton; A Thrasher; D Goldblatt; L Parker; A J Cant Journal: Clin Exp Immunol Date: 2008-05 Impact factor: 4.330
Authors: David C Thomas; Louis-Marie Charbonnier; Andrea Schejtman; Hasan Aldhekri; Eve L Coomber; Elizabeth R Dufficy; Anne E Beenken; James C Lee; Simon Clare; Anneliese O Speak; Adrian J Thrasher; Giorgia Santilli; Hamoud Al-Mousa; Fowzan S Alkuraya; Talal A Chatila; Kenneth G C Smith Journal: J Allergy Clin Immunol Date: 2018-10-09 Impact factor: 10.793
Authors: Paulina Tran; Laura Gober; Elizabeth K Garabedian; Ramsay L Fuleihan; Jennifer M Puck; Kathleen E Sullivan; Jonathan M Spergel; Melanie A Ruffner Journal: Front Immunol Date: 2022-09-23 Impact factor: 8.786